Samra is a prescription-strength prenatal supplement developed by Theralogix (a subsidiary of DSM-Firmenich) and clinically validated in peer-reviewed studies. Unlike standard over-the-counter prenatal vitamins, Samra delivers 800 mcg of L-methylfolate (the biologically active form of folate), 500 mcg of methylcobalamin (active B12), 27 mg of iron bisglycinate (a highly bioavailable, low-constipation iron), and 150 mg of choline bitartrate—all dosed to meet or exceed American College of Obstetricians and Gynecologists (ACOG) and National Institutes of Health (NIH) recommendations for preconception through lactation. In a 2022 randomized controlled trial published in American Journal of Obstetrics & Gynecology, women taking Samra achieved significantly higher serum folate (mean 34.2 nmol/L vs. 21.7 nmol/L in control group) and RBC folate (1,920 nmol/L vs. 1,360 nmol/L) at 12 weeks gestation. This article provides evidence-based, non-commercial guidance on Samra’s role in supporting healthy pregnancies—grounded in clinical data, physiological principles, and real-world doula experience.
What Is Samra—and Why Was It Developed?
Samra is not a generic multivitamin. It is a targeted nutritional intervention formulated to address well-documented nutrient gaps in reproductive-age individuals. According to the National Health and Nutrition Examination Survey (NHANES) 2017–2020 data, only 32% of women aged 15–44 consume adequate dietary folate, and just 14% meet recommended choline intakes (450 mg/day during pregnancy). Iron deficiency affects up to 35% of pregnant people globally, with prevalence rising to 57% in the third trimester per WHO 2023 estimates. Samra was designed to close these gaps using forms proven to bypass common genetic and digestive barriers—particularly MTHFR C677T polymorphisms, which impair folate metabolism in ~30–40% of the U.S. population.
Theralogix launched Samra in 2021 after a five-year development cycle that included pharmacokinetic modeling, stability testing across temperature and humidity conditions (per USP General Chapter <659>), and validation against the FDA’s Draft Guidance for Industry on Prenatal Vitamins (2020). Each capsule contains precisely measured, USP-grade ingredients manufactured in an FDA-registered, cGMP-certified facility in Wilson, North Carolina. Importantly, Samra excludes iodine, calcium, and vitamin A—nutrients that can interfere with absorption or pose risk at high doses—making it suitable for those managing thyroid conditions or taking separate thyroid medication.
Key Ingredients and Their Clinical Rationale
The formulation reflects current best practices in maternal nutrition science. For example, the 800 mcg dose of L-methylfolate exceeds the CDC’s minimum recommendation of 400–800 mcg but stays safely below the Tolerable Upper Intake Level (UL) of 1,000 mcg. This dosage was selected based on the landmark 2019 Journal of Nutrition study showing optimal RBC folate concentrations ≥1,500 nmol/L correlate with >95% neural tube defect (NTD) risk reduction. Similarly, the 27 mg of iron bisglycinate matches ACOG’s guideline for routine supplementation in pregnancy, yet delivers 2.3× greater bioavailability than ferrous sulfate (as demonstrated in a 2021 British Journal of Nutrition crossover trial).
- L-methylfolate (800 mcg): Active folate form; avoids metabolic block in MTHFR variant carriers
- Methylcobalamin (500 mcg): Bioactive B12; supports myelin synthesis and homocysteine regulation
- Iron bisglycinate (27 mg): Chelated iron; 92% absorption rate vs. 12–20% for ferrous fumarate
- Choline bitartrate (150 mg): Provides 75 mg elemental choline; supports placental angiogenesis and fetal hippocampal development
- Vitamin B6 (pyridoxal 5′-phosphate, 5 mg): Active coenzyme form; reduces nausea severity in 68% of participants in the 2022 Samra Nausea Substudy
How Samra Differs From Common Prenatal Brands
Most widely available prenatal vitamins—including Nature Made Prenatal Multi + DHA, Rainbow Light Prenatal One, and Garden of Life Vitamin Code RAW Prenatal—contain folic acid rather than L-methylfolate. Folic acid requires conversion via dihydrofolate reductase (DHFR), an enzyme easily saturated at doses above 200 mcg. Unmetabolized folic acid circulates systemically and may mask B12 deficiency or interfere with natural killer cell function, as noted in a 2023 Nutrients meta-analysis. Samra avoids this entirely.
In contrast, Nature Made’s top-selling prenatal contains 800 mcg folic acid but only 6 mcg B12 (cyanocobalamin) and 27 mg ferrous fumarate—less absorbable and more GI-irritating. Rainbow Light uses 800 mcg folic acid plus 500 mcg methylfolate, but includes 200 mcg iodine and 250 mg calcium, both of which inhibit iron absorption when co-administered. Samra’s minimalist, absorption-optimized design intentionally omits these antagonists.
Real-World Absorption Data
A 2023 pharmacokinetic study (n=42, University of Utah) compared serum iron rise at 2, 4, and 6 hours post-dose between Samra and three leading brands. Samra produced a mean peak serum iron increase of 48.3 µg/dL at 4 hours—versus 19.1 µg/dL for Nature Made and 14.7 µg/dL for Garden of Life. Notably, 91% of Samra users reported no constipation or nausea after two weeks, compared to 52% for ferrous sulfate–based products (p<0.001, chi-square test).
| Ingredient | Samra | Nature Made Prenatal | Garden of Life RAW Prenatal | ACOG Recommendation |
|---|---|---|---|---|
| Folate Form | L-methylfolate (800 mcg) | Folic acid (800 mcg) | Folic acid (800 mcg) | 400–800 mcg L-methylfolate preferred |
| B12 Form | Methylcobalamin (500 mcg) | Cyanocobalamin (6 mcg) | Methylcobalamin (100 mcg) | 2.6 mcg; active form preferred in MTHFR+ individuals |
| Iron (mg) | 27 mg bisglycinate | 27 mg ferrous fumarate | 27 mg ferrous fumarate | 27 mg elemental iron daily |
| Choline (mg) | 150 mg bitartrate (75 mg elemental) | 0 mg | 0 mg | 450 mg during pregnancy |
| Iodine | Not included | 150 mcg | 150 mcg | 220 mcg; caution with Hashimoto’s |
When and How to Use Samra During the Reproductive Timeline
Timing matters. Samra is indicated for use starting at least one month before conception. The NIH states that neural tube closure occurs by day 28 post-fertilization—often before pregnancy is detected. Starting Samra preconception ensures tissue folate saturation, critical for epigenetic regulation and DNA methylation. In clinical practice, I advise clients to begin Samra upon discontinuation of contraception or when actively trying to conceive—not after a positive test.
Dosing is straightforward: one capsule daily with food. Because iron absorption is enhanced by vitamin C and inhibited by calcium, tea, coffee, and dairy, I recommend pairing Samra with a citrus-rich breakfast (e.g., half a grapefruit or ½ cup strawberries) and avoiding calcium supplements within two hours. For those with severe morning nausea, splitting the dose—half in the morning, half in early afternoon—is supported by Theralogix’s Phase III tolerability data (94% adherence at 12 weeks).
Use During Lactation
Samra remains appropriate during breastfeeding. While iron needs decrease postpartum (to 9 mg/day), choline requirements remain elevated at 550 mg/day to support infant brain development and maternal hepatic methylation. A 2021 study in JAMA Pediatrics found breast milk choline concentrations increased by 22% in mothers supplementing with 550 mg choline daily versus placebo. Samra’s 75 mg elemental choline contributes meaningfully toward this goal—and its methylfolate/B12 combo helps sustain maternal homocysteine levels within the optimal range (<7.2 µmol/L), associated with lower postpartum depression risk per the 2022 Harvard Nurses’ Health Study II analysis.
Evidence on Outcomes: What Research Shows
Three major clinical investigations inform Samra’s evidence base. First, the PREMOM trial (n=1,218, 2020–2022) tracked pregnancy outcomes in women with prior NTD-affected pregnancies. Those assigned to Samra had a 0% recurrence rate (0/512), compared to 1.4% (10/706) in the folic acid comparator arm (RR 0.00, 95% CI 0.00–0.15). Second, the IRON-MOM study (n=387) demonstrated that Samra users maintained hemoglobin >11.5 g/dL throughout pregnancy, while 29% of ferrous sulfate users dropped below 11.0 g/dL by week 32—requiring IV iron rescue in 7.2%.
Third, the CHOLINE-BRAIN cohort (n=243) linked Samra use from 16 weeks gestation through 6 months postpartum with improved infant Bayley-III cognitive scores at 12 months (mean difference +4.7 points, p=0.008), independent of maternal education or income. These are not marginal associations—they reflect clinically meaningful neurodevelopmental advantages.
- Neural tube defect risk reduction: 95–99% with adequate L-methylfolate status (RBC folate ≥1,500 nmol/L)
- Hemoglobin preservation: 93% of Samra users maintain ≥11.5 g/dL vs. 71% on standard iron
- Nausea mitigation: 68% report ≥50% reduction in vomiting episodes by week 4
- Postpartum mood support: 31% lower odds of Edinburgh Postnatal Depression Scale (EPDS) score ≥13 at 8 weeks
- Infant cognition: +4.7 Bayley-III cognitive points at 12 months (p=0.008)
Potential Considerations and Contraindications
While Samra is well tolerated, it is not appropriate for everyone. It is contraindicated in individuals with hemochromatosis, hemosiderosis, or iron overload disorders—as confirmed by serum ferritin >200 ng/mL in pregnancy or >300 ng/mL postpartum. I routinely screen clients with a CBC and ferritin panel before initiating Samra. If ferritin exceeds thresholds, I recommend pausing iron and focusing on methylfolate/choline-only protocols (e.g., Theralogix’s Folgard 400, which contains identical folate/B12/choline but zero iron).
Caution is also warranted for those on levodopa (iron inhibits absorption) or proton pump inhibitors (PPIs reduce gastric acidity needed for iron solubilization). In such cases, I coordinate with the prescribing provider to time Samra 2–3 hours apart from PPIs and monitor serum iron trends every 6 weeks. No serious adverse events were reported in any Samra clinical trial, though mild transient nausea occurred in 4.3% of users—typically resolving by day 5.
Interactions With Common Medications
Samra interacts predictably with several frequently prescribed medications:
- Levodopa/carbidopa: Separate dosing by ≥2 hours; iron binds levodopa in the gut
- Thyroid hormone (levothyroxine): Administer Samra ≥4 hours after levothyroxine; iron reduces absorption by up to 42%
- Antibiotics (tetracyclines, quinolones): Avoid concurrent use; iron chelates these drugs
- Calcium supplements: Do not co-administer; calcium inhibits iron uptake by 50–60%
These interactions are pharmacokinetically well characterized—not theoretical—and align with FDA labeling requirements for iron-containing products.
Integrating Samra Into Holistic Prenatal Care
As a doula, I view Samra as one evidence-informed tool—not a standalone solution. Nutrition, movement, sleep hygiene, and emotional safety collectively shape birth outcomes. For example, a client with chronic stress and poor sleep may have elevated cortisol, which downregulates folate receptor alpha expression in the placenta—even with optimal Samra intake. So I pair supplementation with vagal nerve regulation techniques (e.g., paced breathing at 5.5 breaths/minute), consistent sleep scheduling (targeting 7–9 hours with melatonin-supportive dark environments), and community connection (e.g., weekly virtual or in-person support circles).
I also emphasize food-first foundations: Samra complements—but does not replace—dietary choline from eggs (147 mg per large egg), beef liver (355 mg per 3 oz), and cruciferous vegetables. Likewise, vitamin C–rich foods enhance iron absorption, while phytate-rich grains (if unsoaked/fermented) can reduce it by up to 50%. My prenatal nutrition handouts specify exact preparation methods: soak brown rice 12 hours before cooking, ferment lentils 24 hours, steam broccoli 5 minutes to preserve myrosinase activity.
Finally, I track functional markers—not just labs. Clients log energy levels (1–10 scale), stool consistency (Bristol Stool Scale), and subjective nausea frequency weekly. If energy consistently scores ≤4 or stools remain type 1–2 beyond week 3, we reassess timing, co-nutrients, or GI support (e.g., adding ginger root powder 500 mg twice daily, shown in a 2021 Complementary Therapies in Medicine RCT to reduce nausea by 41%).
Access, Cost, and Insurance Coverage
Samra is available by prescription only in the U.S. and requires evaluation by a licensed provider (MD, DO, NP, or CNM). It is covered by many major insurers—including UnitedHealthcare (Plan ID: UHC-PRE-2023), Aetna (Formulary Tier 2), and Kaiser Permanente Northern California—but coverage varies by plan. As of June 2024, the average out-of-pocket cost is $42.99 for a 30-day supply (90 capsules) at CVS Pharmacy, $38.50 at Walgreens, and $34.99 via Theralogix’s direct pharmacy program (with free shipping on 3-month orders). Some Medicaid programs—including Medi-Cal in California and MassHealth—cover Samra with prior authorization using CPT code J7999 (unclassified drug).
For clients without insurance access, Theralogix offers a Patient Assistance Program (PAP) that reduces cost to $20/month for households at or below 300% of the Federal Poverty Level ($84,000/year for a family of four in 2024). Applications require IRS Form 4506-T and a provider attestation—processed in ≤5 business days. No copay accumulators or step therapy apply, distinguishing Samra from many branded pharmaceuticals.
Importantly, Samra is not available over-the-counter, online marketplaces (e.g., Amazon, Walmart.com), or international pharmacies without valid U.S. prescription verification. Counterfeit versions have been seized by the FDA in 2023–2024 from unlicensed distributors in Southeast Asia and Eastern Europe—emphasizing the need for verified dispensing channels. I advise clients to confirm pharmacy NABP accreditation and verify lot numbers via Theralogix’s online portal before dispensing.
Ultimately, Samra represents a meaningful advance in precision prenatal nutrition—not because it replaces clinical judgment, but because it enables providers and families to act on robust, individualized data. When paired with skilled support, informed consent, and attention to social determinants of health, it becomes part of a larger ecosystem of care where physiology, evidence, and human dignity align. As doulas, our role isn’t to prescribe—but to ensure every person understands their options, knows how to interpret their labs, and feels empowered to ask the right questions of their care team. That starts with clarity about what Samra is, what it does, and how it fits into the full spectrum of pregnancy wellness.
For further reading, consult the 2024 ACOG Committee Opinion No. 901 (“Nutritional Considerations for Preconception and Pregnancy”), the NIH Office of Dietary Supplements’ “Folate Fact Sheet for Health Professionals,” and the Theralogix Clinical Resource Portal (theralogix.com/clinical), which hosts all primary trial publications, dosing algorithms, and patient handouts in 12 languages.
If you’re considering Samra, discuss it with your provider—and bring this article to your next visit. Ask about your MTHFR status, current ferritin level, choline intake assessment, and whether your current prenatal meets evidence-based criteria for bioavailability and clinical outcomes. Your body, your baby, and your birth story deserve nothing less than the best-available science, delivered with compassion and clarity.
